|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | C07D 401/14 | (2006.01) |
| A61K 31/496 | (2006.01) | ||
| A61P 29/00 | (2006.01) |
| (11) | Number of the document | 2552906 |
| (13) | Kind of document | T |
| (96) | European patent application number | 11710087.5 |
| Date of filing the European patent application | 2011-03-11 | |
| (97) | Date of publication of the European application | 2013-02-06 |
| (45) | Date of publication and mention of the grant of the patent | 2016-01-06 |
| (46) | Date of publication of the claims translation | 2016-04-11 |
| (86) | Number | PCT/US2011/028168 |
| Date | 2011-03-11 |
| (87) | Number | WO 2011/123232 |
| Date | 2011-10-06 |
| (30) | Number | Date | Country code |
| 319015 P | 2010-03-30 | US |
| (72) |
CHATURVEDULA, Prasad V., US
DUBOWCHIK, Gene M., US
MACOR, John E., US
|
| (73) |
Bristol-Myers Squibb Company,
Route 206 and Province Line Road, Princeton, NJ 08543,
US
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | CGRP receptoriaus antagonistas |
| CGRP RECEPTOR ANTAGONIST |
| Payment date | Validity (years) | Amount | |
| 2025-02-10 | 15 | 289.00 EUR |
| 2026-03-11 |